Emerging technology and platforms for cardiotoxicity testing

Toxicol Appl Pharmacol. 2020 Dec 1:408:115262. doi: 10.1016/j.taap.2020.115262. Epub 2020 Oct 2.

¹ Institute of Molecular Cardiology, University of Louisville, Louisville, KY 40292, United States; Diabetes and Obesity Center, University of Louisville, Louisville, KY 40292, United States; Christina Lee Brown Envirome Institute, University of Louisville, Louisville, KY 40292, United States; Department of Medicine, University of Louisville, Louisville, KY 40292, United States.
² Diabetes and Obesity Center, University of Louisville, Louisville, KY 40292, United States; Christina Lee Brown Envirome Institute, University of Louisville, Louisville, KY 40292, United States; Department of Medicine, University of Louisville, Louisville, KY 40292, United States. Electronic address: dj.conklin@louisville.edu.

Abstract

Keywords: Anticancer drugs; Cardiomyocyte; Embryonic stem cells; High throughput; Human-induced pluripotent stem cells; Toxicity.